Jacomedic AS
ASDissolvedOrg 986938230Dalstuvegen 18, 2340 LøtenWholesale of pharmaceutical and medical goods· NACE 4646Est. 2004 · 22 years old1 employeeshttps://www.jacomedic.no
Loading company…
Overview
Jacomedic AS is a Norwegian AS based in Løten, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2004, the company has 1 employee and reported revenue of NOK 37.2m in its latest annual filing.
Revenue 2022
37.2M NOK
+15% vs 2021
EBITDA margin
17.2 %
−3% vs 2021
Net profit 2022
4.9M NOK
-3% vs 2021
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
9.3 %
WeakAmong the 30% lowest rated companies in the industry
20182022
Liquidity ratioCurrent assets ÷ Short-term debt
1.1×
WeakAmong the 30% lowest rated companies in the industry
20182022
Return on assets (ROA)Net profit ÷ Total assets × 100
23.1 %
Very strongAmong the 20% highest rated companies in the industry
20182022
EBITDA — year on year
NOK millionsKey figures
Annual report 2022| Revenue | 37.2M NOK | +15% |
| EBITDA | 6.4M NOK | -3% |
| Net profit | 4.9M NOK | -3% |
| Total assets | 21M NOK | +11% |
| Equity | 1.9M NOK | -80% |
| Employees | 1 | — |
Company information
Legal name
JACOMEDIC AS
Org number
986938230
Legal form
Aksjeselskap
NACE code
Founded
8 May 2004 · 22 years
Share capital
NOK 700,000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Styrets leder og daglig leder hver for seg.
Company purpose
Handel, service, rådgivning, import- og agenturvirksomhet og alt som står i naturlig forbindelse med dette samt deltagelse i andre selskaper og virksomheter med tilsvarende formål, samt kjøp og salg av fast eiendom.
(no translation available)
Contact
Address
Dalstuvegen 18, 2340 Løten
Phone
+47 69 26 29 00
Email
post@jacomedic.no
Website
https://www.jacomedic.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2022), Jacomedic AS reported revenue of NOK 37.2m, an increase of 15% on the year before. The figures on this page draw on 5 annual filings covering 2018 to 2022. The bottom line showed a net profit of NOK 4.9m, and the EBITDA margin stood at 17.2%.
At the end of 2022, equity financed 9.3% of the balance sheet, and current assets covered short-term debt 1.1 times.
Financials
Revenue
NOK millionsEBITDA
NOK millionsIncome statement
NOK thousands| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 37,151 | 32,444 | 44,755 | 27,783 | 24,742 |
| Staff expenses | -7,059 | -5,238 | -6,436 | -0 | -5,135 |
| EBITDA | 6,392 | 6,568 | 10,854 | 3,328 | 3,285 |
| Depreciation & amort. | -149 | -161 | -183 | -304 | -224 |
| EBIT | 6,243 | 6,407 | 10,672 | 3,024 | 3,061 |
| Net financials | -2 | -0 | -66 | -27 | -21 |
| Profit before tax | 6,241 | 6,407 | 10,606 | 2,997 | 3,040 |
| Tax | 1,379 | 1,413 | 2,339 | 662 | 704 |
| Net profit | 4,862 | 4,994 | 8,267 | 2,335 | 2,336 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
NOK thousands| Item | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Total assets | 21,007 | 18,893 | 19,934 | 11,639 | 10,704 |
| Equity | 1,949 | 9,587 | 7,593 | 4,326 | 3,691 |
| Long-term debt | 29 | 30 | 31 | 780 | 825 |
| Short-term debt | 19,030 | 9,275 | 12,310 | 6,533 | 6,188 |
| Total debt | 19,058 | 9,306 | 12,341 | 7,313 | 7,013 |
Financial ratios
5-year trendEBITDA margin
17.2 %
20182022
Equity ratio
9.3 %
WeakAmong the 30% lowest rated companies in the industry
20182022
Return on equity
249.5 %
Very strongAmong the 10% highest rated companies in the industry
20182022
Net profit margin
13.1 %
Very strongAmong the 20% highest rated companies in the industry
20182022
Asset turnover
1.77×
AverageAround the average of companies in the same industry
20182022
Debt / equity
9.78×
Very weakAmong the 10% lowest rated companies in the industry
20182022
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginAverage
Around the average of companies in the same industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginVery strong
Among the 20% highest rated companies in the industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery strong
Among the 20% highest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Very strong
Among the 10% highest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very strong
Among the 20% highest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very strong
Among the 10% highest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very strong
Among the 10% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery strong
Among the 20% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 40% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalAverage
Around the average of companies in the same industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioStrong
Among the 40% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioWeak
Among the 30% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioWeak
Among the 30% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtStrong
Among the 30% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtStrong
Among the 30% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery strong
Among the 10% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 40% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery strong
Among the 20% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverAverage
Around the average of companies in the same industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalAverage
Around the average of companies in the same industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HR Chief Executive Officer | Chief Executive Officer | 2023 |
Former (1)
PE Chief Executive Officer | Chief Executive Officer | 2020 – 2023 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HR Chairman | Chairman | 2023 |
LE Board of Directors | Board of Directors | 2023 |
Former (6)
PE Board of Directors | Board of Directors | 2020 – 2023 |
TN Board of Directors | Board of Directors | 2020 – 2022 |
LB Board of Directors | Board of Directors | 2020 – 2023 |
SH Board of Directors | Board of Directors | 2020 – 2023 |
KE Chairman | Chairman | 2020 – 2023 |
MR Board of Directors | Board of Directors | 2020 – 2023 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 23.13% | 23.13% | 2020 | |
| Company | 10% | 10% | 2021 | |
| Company | 100% | 100% | 2023 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Jacomedic As
Jacomedic AS Board network connections
Board members of Jacomedic AS also hold positions in 191 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Nortvedt | Board of Directors | 159 companiesMany roles |
| Henrik Rustad | Chief Executive Officer | 8 companiesMany roles |
| Solveig Henriette Alsvik | Board of Directors | 7 companiesMany roles |
| Morten Rindal Øvsteng | Board of Directors | 7 companiesMany roles |
| Petter Ek Jacobsen | Chief Executive Officer | 6 companiesMany roles |
| Lars Erik Stensvehagen | Board of Directors | 4 companies |
Frequently asked questions
What is the Org number of Jacomedic AS?
Jacomedic AS is registered with Brønnøysundsregistrene under Org 986938230.
What is the revenue of Jacomedic AS?
Jacomedic AS reported revenue of NOK 37.2m in 2022.
How many employees does Jacomedic AS have?
Jacomedic AS employs 1 people as of the latest annual report.
Who is the CEO of Jacomedic AS?
Henrik Rustad is the CEO of Jacomedic AS, in role since 2023.
Who is the chairman of Jacomedic AS?
Henrik Rustad chairs the board of Jacomedic AS, in role since 2023.
Where is Jacomedic AS headquartered?
Jacomedic AS's registered address is Dalstuvegen 18.